Articles
NANS Urges Humana to End Barriers to Peripheral Nerve Stimulation Access
NANS spearheaded a letter to Humana executives after members expressed serious concerns regarding ongoing prior authorization delays and denials for Peripheral Nerve Stimulation (PNS) treatments for Humana Medicare Advantage beneficiaries.
Humana Imposes Further Restrictions on Medicare Coverage for Neuromodulation Therapies
Open enrollment for Medicare Advantage runs October 15 – December 7. Physicians should be aware that Humana’s Medicare Advantage plan has some of the most rigorous and strict prior authorization requirements for neuromodulation therapies like spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS).
Humana Revises Medicare Advantage Policy Allowing PNS Treatment for Chronic Pain Under Certain Criteria
Humana revised its Medicare Advantage policy regarding coverage of PNS for chronic pain after NANS issued a statement on behalf of 12 medical societies through the Multisociety Pain Workgroup.
NANS leads response to Humana’s new policy that excludes coverage of PNS
In January 2024, Humana issued Medicare Advantage policy HUM-1140-000, excluding from coverage peripheral nerve stimulators (PNS) for treating chronic pain. NANS issued a statement on behalf of 12 medical societies objecting to the policy.